Viatris Inc (VTRS) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$17.19

From 52W high−5.10%

Volume15.46M

Market cap$19.47B

P/E (TTM)—

P/S (TTM)1.3x

Div yield2.12%

Key dataSep 18, 2026

Open

$17.19

From 52W high

−5.10%

Volume

15.46M

Market cap

$19.47B

ValuationView details →

P/E (Fwd)

6.7x

EV/EBITDA

12.0x

P/E (TTM)

—

RSI (14)

55.6

MomentumView details →

1D Return

−1.05%

YTD Return

+36.36%

SummaryUpdated Jun 1, 2026

Viatris Inc. (NASDAQ:VTRS) is a global healthcare company formed in 2020 through the merger of Mylan N.V. and Pfizer's Upjohn division. The company traces its roots back to 1961 and represents one of the world's largest generic and specialty pharmaceutical companies. Headquartered in Canonsburg, Pennsylvania, Viatris operates across more than 165 countries and serves over one billion patients annually with a diverse portfolio of prescription medicines, biosimilars, and active pharmaceutical ingredients.

Ask drillr about Viatris Inc →

ValuationView details →

P/E (Fwd)

6.7x

P/E (TTM)

—

EV/EBITDA

12.0x

EV/Sales

2.1x

P/S (TTM)

1.3x

P/B (TTM)

1.4x

ProfitabilityView details →

Gross Margin

34.83%

Net Margin

−2.79%

EBITDA Margin

17.92%

ROE (TTM)

−2.88%

ROA (TTM)

−1.17%

Asset Turnover

0.41x

GrowthView details →

Revenue YoY

+4.40%

EPS YoY

+87.61%

FCF YoY

+10.50%

Revenue CAGR 3Y

−4.20%

EPS CAGR 3Y

—

EBITDA YoY

+635.33%

MomentumView details →

1D Return

−1.05%

YTD Return

+36.36%

1Y Return

+71.49%

RSI (14)

55.6

vs 50D SMA

+0.99%

vs 200D SMA

+13.19%

Capital & dividendView details →

Debt/Equity

0.96x

Current Ratio

1.58x

Quick Ratio

0.96x

Div Yield

2.12%

Div Rate

$0.36

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

$0.69

EPS Surprise

14.81%

Beats (12Q)

7/12

Next Q EPS Est

$0.65

Avg Surprise (4Q)

−30.17%

Rev Surprise

2.26%

Financials snapshotView financials →

Revenue (TTM)

14.74B

Net Income (TTM)

−410.70M

Op. CF (TTM)

2.33B

Next earningsNov 5, 2026 →

Latest newsMore news →

Japan's Ministry of Health, Labour and Welfare approved Viatris' WAKIX (pitolisant) for narcolepsy and for excessive daytime sleepiness associated with obstructive sleep apnea syndrome.4d ago

The Supreme Court of India upheld the Telangana High Court's decision not to initiate contempt proceedings against IQuest Enterprises Pvt. Ltd., ruling that a clarificatory statement made before a court does not constitute a binding undertaking for contempt purposes.19d ago

Similar companies

皓元医药688131.SH HUTCHMED (China) Limited00013.HK 哈药股份600664.SH Livzon Pharmaceutical Group Inc.01513.HK Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited00874.HK Aprogen Biologics Inc.003060.KS Find similar companies →

Latest newsMore news →

Japan's Ministry of Health, Labour and Welfare approved Viatris' WAKIX (pitolisant) for narcolepsy and for excessive daytime sleepiness associated with obstructive sleep apnea syndrome.4d ago The Supreme Court of India upheld the Telangana High Court's decision not to initiate contempt proceedings against IQuest Enterprises Pvt. Ltd., ruling that a clarificatory statement made before a court does not constitute a binding undertaking for contempt purposes.19d ago